+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Therapeutic BCG Vaccine Market - Global Forecast 2026-2032- Product Image
Therapeutic BCG Vaccine Market - Global Forecast 2026-2032- Product Image
New

Therapeutic BCG Vaccine Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 180 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 4986049
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The therapeutic BCG vaccine market is evolving rapidly, presenting new opportunities and requiring strategic oversight from senior leaders. To stay competitive, decision-makers must integrate clinical innovation, dependable supply chain models, and changing regional regulations into scalable, resilient strategies.

Market Snapshot: Therapeutic BCG Vaccine Market Overview

The therapeutic BCG vaccine market grew from USD 63.17 million in 2025 to USD 70.34 million in 2026 and is expected to achieve a compound annual growth rate (CAGR) of 4.62%, reaching USD 86.71 million by 2032. This steady progression is shaped by greater integration in oncology and autoimmune care, consistent clinical validation, and increasing global dissemination. These patterns are influenced by shifting healthcare needs, new care models, and a broadening landscape for vaccination access.

Scope & Segmentation of the Therapeutic BCG Vaccine Market

  • Route of Administration: Covers both intravesical and intradermal delivery, each requiring distinct clinical workflows, facility preparedness, and specialized staff training to achieve intended therapeutic results.
  • Therapeutic Indications: Extends across oncology with varied bladder cancer subtypes and melanoma (cutaneous and mucosal), as well as autoimmune disorders like type 1 diabetes, each with unique clinical development and market access requirements.
  • End-User Settings: Includes hospitals, ambulatory surgical centers, oncology clinics, and urology clinics, each presenting differentiated demands for equipment, workflow integration, and revenue management.
  • Regions: Encompasses the Americas, EMEA (Europe, Middle East & Africa), and Asia-Pacific, each shaped by specific regulatory protocols, payer systems, and clinical practice standards that directly inform commercialization planning.
  • Stakeholder Perspectives: Considers clinicians, hospital executives, manufacturers, distributors, and regulatory authorities, with varying priorities for adoption, patient outcomes, supply reliability, and policy compliance.
  • Manufacturing Technology: Focuses on scalable production, advances in quality assurance, and supply chain risk mitigation, with technology adoption increasingly critical to ensuring long-term viability.

Key Takeaways for Senior Decision-Makers

  • Therapeutic BCG is established as a core element in current immunology and oncology care, supported by a proven safety profile and multiple mechanisms of action.
  • Increasing complexity in treatment protocols now includes greater emphasis on combination therapies, expanded administration routes, and individualized patient pathways, improving care effectiveness.
  • Manufacturing and quality improvements are stabilizing supply availability, minimizing disruptions, and creating avenues for product differentiation and brand positioning.
  • Strengthened regulatory scrutiny enforces clinical comparability, demanding heightened compliance and thorough post-market monitoring for all stakeholders.
  • Payer diversity and the adoption of value-based reimbursement increase reliance on robust evidence and economic modeling to maintain institutional and patient value.

Tariff Impact: U.S. Policy Shifts and Supply Chain Resilience

Ongoing shifts in U.S. tariff policy have prompted businesses in the therapeutic BCG vaccine market to reevaluate procurement and supplier strategies. As a result, organizations face increased landed costs and additional operational complexities, especially for products requiring specialized or cold chain logistics. Companies investing in domestic or tariff-exempt sourcing stand to gain from enhanced supply transparency and reduced vulnerability. Procurement leaders are prioritizing traceable, onshore partnerships to stabilize continuity and manage risk effectively.

Methodology & Data Sources

This market analysis utilizes structured interviews with clinicians, procurement directors, and supply chain specialists. Secondary insights are corroborated with peer-reviewed research, clinical registries, and documents from regulatory bodies. Findings are validated using scenario analysis to ensure accurate representation of the market landscape and identification of actionable strategy points.

Why This Report Matters to Market Leaders

  • Provides executives with actionable frameworks, enabling alignment of clinical data, advanced manufacturing, and global market entry strategies for sustained growth in the therapeutic BCG vaccine market.
  • Supports procurement and compliance teams as they navigate regulatory uncertainty, build resilient supply channels, and maintain seamless access for healthcare providers and patients.
  • Equips decision-makers to create operational programs that fit the needs of hospitals and specialty clinics, reducing adoption risk while ensuring both regulatory compliance and optimal patient management.

Conclusion

The therapeutic BCG vaccine market’s continued advancement depends on innovation, agile cross-sector collaboration, and strategic adaptation. Consistent supply and operational rigor remain central to securing long-term leadership in this evolving space.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Therapeutic BCG Vaccine Market, by Route of Administration
8.1. Intradermal Injection
8.2. Intravesical Administration
9. Therapeutic BCG Vaccine Market, by Type
9.1. Immune BCG
9.2. Therapy BCG
10. Therapeutic BCG Vaccine Market, by Application
10.1. Bladder Cancer
10.1.1. Carcinoma In Situ
10.1.2. Non-Muscle Invasive
10.2. Melanoma
10.2.1. Cutaneous Melanoma
10.2.2. Mucosal Melanoma
10.3. Type 1 Diabetes
11. Therapeutic BCG Vaccine Market, by End User
11.1. Ambulatory Surgical Centers
11.2. Clinics
11.2.1. Oncology Clinics
11.2.2. Urology Clinics
11.3. Hospitals
12. Therapeutic BCG Vaccine Market, by Region
12.1. Americas
12.1.1. North America
12.1.2. Latin America
12.2. Europe, Middle East & Africa
12.2.1. Europe
12.2.2. Middle East
12.2.3. Africa
12.3. Asia-Pacific
13. Therapeutic BCG Vaccine Market, by Group
13.1. ASEAN
13.2. GCC
13.3. European Union
13.4. BRICS
13.5. G7
13.6. NATO
14. Therapeutic BCG Vaccine Market, by Country
14.1. United States
14.2. Canada
14.3. Mexico
14.4. Brazil
14.5. United Kingdom
14.6. Germany
14.7. France
14.8. Russia
14.9. Italy
14.10. Spain
14.11. China
14.12. India
14.13. Japan
14.14. Australia
14.15. South Korea
15. United States Therapeutic BCG Vaccine Market
16. China Therapeutic BCG Vaccine Market
17. Competitive Landscape
17.1. Market Concentration Analysis, 2025
17.1.1. Concentration Ratio (CR)
17.1.2. Herfindahl Hirschman Index (HHI)
17.2. Recent Developments & Impact Analysis, 2025
17.3. Product Portfolio Analysis, 2025
17.4. Benchmarking Analysis, 2025
17.5. AJ Vaccines A/S
17.6. Biomed Lublin S.A.
17.7. China National Biotec Group Co., Ltd.
17.8. GreenSignal Bio Pharma Limited
17.9. Instituto Butantan
17.10. InterVax Ltd.
17.11. Japan BCG Laboratory
17.12. Laboratorios Reig Jofre S.A.
17.13. Merck & Co., Inc.
17.14. PT Bio Farma (Persero)
17.15. Sanofi S.A.
17.16. Serum Institute of India Pvt. Ltd.
17.17. Statens Serum Institut
17.18. Torlak Institute of Virology, Vaccines and Sera
List of Figures
FIGURE 1. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL THERAPEUTIC BCG VACCINE MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL THERAPEUTIC BCG VACCINE MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. UNITED STATES THERAPEUTIC BCG VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 12. CHINA THERAPEUTIC BCG VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY INTRADERMAL INJECTION, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY INTRADERMAL INJECTION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY INTRADERMAL INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY INTRAVESICAL ADMINISTRATION, BY REGION, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY INTRAVESICAL ADMINISTRATION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY INTRAVESICAL ADMINISTRATION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY IMMUNE BCG, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY IMMUNE BCG, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY IMMUNE BCG, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY THERAPY BCG, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY THERAPY BCG, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY THERAPY BCG, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY BLADDER CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY BLADDER CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY BLADDER CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY BLADDER CANCER, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY CARCINOMA IN SITU, BY REGION, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY CARCINOMA IN SITU, BY GROUP, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY CARCINOMA IN SITU, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY NON-MUSCLE INVASIVE, BY REGION, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY NON-MUSCLE INVASIVE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY NON-MUSCLE INVASIVE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY MELANOMA, BY REGION, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY MELANOMA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY MELANOMA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY CUTANEOUS MELANOMA, BY REGION, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY CUTANEOUS MELANOMA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY CUTANEOUS MELANOMA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY MUCOSAL MELANOMA, BY REGION, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY MUCOSAL MELANOMA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY MUCOSAL MELANOMA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE 1 DIABETES, BY REGION, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE 1 DIABETES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE 1 DIABETES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY ONCOLOGY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY ONCOLOGY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY ONCOLOGY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY UROLOGY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY UROLOGY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY UROLOGY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 58. AMERICAS THERAPEUTIC BCG VACCINE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 59. AMERICAS THERAPEUTIC BCG VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 60. AMERICAS THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 61. AMERICAS THERAPEUTIC BCG VACCINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 62. AMERICAS THERAPEUTIC BCG VACCINE MARKET SIZE, BY BLADDER CANCER, 2018-2032 (USD MILLION)
TABLE 63. AMERICAS THERAPEUTIC BCG VACCINE MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
TABLE 64. AMERICAS THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 65. AMERICAS THERAPEUTIC BCG VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 66. NORTH AMERICA THERAPEUTIC BCG VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 67. NORTH AMERICA THERAPEUTIC BCG VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 68. NORTH AMERICA THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 69. NORTH AMERICA THERAPEUTIC BCG VACCINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 70. NORTH AMERICA THERAPEUTIC BCG VACCINE MARKET SIZE, BY BLADDER CANCER, 2018-2032 (USD MILLION)
TABLE 71. NORTH AMERICA THERAPEUTIC BCG VACCINE MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
TABLE 72. NORTH AMERICA THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 73. NORTH AMERICA THERAPEUTIC BCG VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 74. LATIN AMERICA THERAPEUTIC BCG VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 75. LATIN AMERICA THERAPEUTIC BCG VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 76. LATIN AMERICA THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 77. LATIN AMERICA THERAPEUTIC BCG VACCINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 78. LATIN AMERICA THERAPEUTIC BCG VACCINE MARKET SIZE, BY BLADDER CANCER, 2018-2032 (USD MILLION)
TABLE 79. LATIN AMERICA THERAPEUTIC BCG VACCINE MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
TABLE 80. LATIN AMERICA THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 81. LATIN AMERICA THERAPEUTIC BCG VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 82. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC BCG VACCINE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 83. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC BCG VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 84. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 85. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC BCG VACCINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 86. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC BCG VACCINE MARKET SIZE, BY BLADDER CANCER, 2018-2032 (USD MILLION)
TABLE 87. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC BCG VACCINE MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
TABLE 88. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 89. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC BCG VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 90. EUROPE THERAPEUTIC BCG VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 91. EUROPE THERAPEUTIC BCG VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 92. EUROPE THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 93. EUROPE THERAPEUTIC BCG VACCINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 94. EUROPE THERAPEUTIC BCG VACCINE MARKET SIZE, BY BLADDER CANCER, 2018-2032 (USD MILLION)
TABLE 95. EUROPE THERAPEUTIC BCG VACCINE MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
TABLE 96. EUROPE THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 97. EUROPE THERAPEUTIC BCG VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 98. MIDDLE EAST THERAPEUTIC BCG VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 99. MIDDLE EAST THERAPEUTIC BCG VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 100. MIDDLE EAST THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 101. MIDDLE EAST THERAPEUTIC BCG VACCINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 102. MIDDLE EAST THERAPEUTIC BCG VACCINE MARKET SIZE, BY BLADDER CANCER, 2018-2032 (USD MILLION)
TABLE 103. MIDDLE EAST THERAPEUTIC BCG VACCINE MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
TABLE 104. MIDDLE EAST THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 105. MIDDLE EAST THERAPEUTIC BCG VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 106. AFRICA THERAPEUTIC BCG VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 107. AFRICA THERAPEUTIC BCG VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 108. AFRICA THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 109. AFRICA THERAPEUTIC BCG VACCINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 110. AFRICA THERAPEUTIC BCG VACCINE MARKET SIZE, BY BLADDER CANCER, 2018-2032 (USD MILLION)
TABLE 111. AFRICA THERAPEUTIC BCG VACCINE MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
TABLE 112. AFRICA THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 113. AFRICA THERAPEUTIC BCG VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 114. ASIA-PACIFIC THERAPEUTIC BCG VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 115. ASIA-PACIFIC THERAPEUTIC BCG VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 116. ASIA-PACIFIC THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 117. ASIA-PACIFIC THERAPEUTIC BCG VACCINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 118. ASIA-PACIFIC THERAPEUTIC BCG VACCINE MARKET SIZE, BY BLADDER CANCER, 2018-2032 (USD MILLION)
TABLE 119. ASIA-PACIFIC THERAPEUTIC BCG VACCINE MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
TABLE 120. ASIA-PACIFIC THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 121. ASIA-PACIFIC THERAPEUTIC BCG VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 122. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 123. ASEAN THERAPEUTIC BCG VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 124. ASEAN THERAPEUTIC BCG VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 125. ASEAN THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 126. ASEAN THERAPEUTIC BCG VACCINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 127. ASEAN THERAPEUTIC BCG VACCINE MARKET SIZE, BY BLADDER CANCER, 2018-2032 (USD MILLION)
TABLE 128. ASEAN THERAPEUTIC BCG VACCINE MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
TABLE 129. ASEAN THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 130. ASEAN THERAPEUTIC BCG VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 131. GCC THERAPEUTIC BCG VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 132. GCC THERAPEUTIC BCG VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 133. GCC THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 134. GCC THERAPEUTIC BCG VACCINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 135. GCC THERAPEUTIC BCG VACCINE MARKET SIZE, BY BLADDER CANCER, 2018-2032 (USD MILLION)
TABLE 136. GCC THERAPEUTIC BCG VACCINE MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
TABLE 137. GCC THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 138. GCC THERAPEUTIC BCG VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 139. EUROPEAN UNION THERAPEUTIC BCG VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 140. EUROPEAN UNION THERAPEUTIC BCG VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 141. EUROPEAN UNION THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 142. EUROPEAN UNION THERAPEUTIC BCG VACCINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 143. EUROPEAN UNION THERAPEUTIC BCG VACCINE MARKET SIZE, BY BLADDER CANCER, 2018-2032 (USD MILLION)
TABLE 144. EUROPEAN UNION THERAPEUTIC BCG VACCINE MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
TABLE 145. EUROPEAN UNION THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 146. EUROPEAN UNION THERAPEUTIC BCG VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 147. BRICS THERAPEUTIC BCG VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 148. BRICS THERAPEUTIC BCG VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 149. BRICS THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 150. BRICS THERAPEUTIC BCG VACCINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 151. BRICS THERAPEUTIC BCG VACCINE MARKET SIZE, BY BLADDER CANCER, 2018-2032 (USD MILLION)
TABLE 152. BRICS THERAPEUTIC BCG VACCINE MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
TABLE 153. BRICS THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 154. BRICS THERAPEUTIC BCG VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 155. G7 THERAPEUTIC BCG VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 156. G7 THERAPEUTIC BCG VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 157. G7 THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 158. G7 THERAPEUTIC BCG VACCINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 159. G7 THERAPEUTIC BCG VACCINE MARKET SIZE, BY BLADDER CANCER, 2018-2032 (USD MILLION)
TABLE 160. G7 THERAPEUTIC BCG VACCINE MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
TABLE 161. G7 THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 162. G7 THERAPEUTIC BCG VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 163. NATO THERAPEUTIC BCG VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 164. NATO THERAPEUTIC BCG VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 165. NATO THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 166. NATO THERAPEUTIC BCG VACCINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 167. NATO THERAPEUTIC BCG VACCINE MARKET SIZE, BY BLADDER CANCER, 2018-2032 (USD MILLION)
TABLE 168. NATO THERAPEUTIC BCG VACCINE MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
TABLE 169. NATO THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 170. NATO THERAPEUTIC BCG VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 171. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 172. UNITED STATES THERAPEUTIC BCG VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 173. UNITED STATES THERAPEUTIC BCG VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 174. UNITED STATES THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 175. UNITED STATES THERAPEUTIC BCG VACCINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 176. UNITED STATES THERAPEUTIC BCG VACCINE MARKET SIZE, BY BLADDER CANCER, 2018-2032 (USD MILLION)
TABLE 177. UNITED STATES THERAPEUTIC BCG VACCINE MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
TABLE 178. UNITED STATES THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 179. UNITED STATES THERAPEUTIC BCG VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 180. CHINA THERAPEUTIC BCG VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 181. CHINA THERAPEUTIC BCG VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 182. CHINA THERAPEUTIC BCG VACCINE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 183. CHINA THERAPEUTIC BCG VACCINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 184. CHINA THERAPEUTIC BCG VACCINE MARKET SIZE, BY BLADDER CANCER, 2018-2032 (USD MILLION)
TABLE 185. CHINA THERAPEUTIC BCG VACCINE MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
TABLE 186. CHINA THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 187. CHINA THERAPEUTIC BCG VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Therapeutic BCG Vaccine market report include:
  • AJ Vaccines A/S
  • Biomed Lublin S.A.
  • China National Biotec Group Co., Ltd.
  • GreenSignal Bio Pharma Limited
  • Instituto Butantan
  • InterVax Ltd.
  • Japan BCG Laboratory
  • Laboratorios Reig Jofre S.A.
  • Merck & Co., Inc.
  • PT Bio Farma (Persero)
  • Sanofi S.A.
  • Serum Institute of India Pvt. Ltd.
  • Statens Serum Institut
  • Torlak Institute of Virology, Vaccines and Sera

Related Topics

Related Reports

Therapeutic BCG Vaccines Market Report 2025 - Product Image

Therapeutic BCG Vaccines Market Report 2025

  • Report
  • 250 Pages
  • Global
From
Therapeutic Bcg Vaccines Market Outlook 2025-2034: Market Share, and Growth Analysis - Product Image

Therapeutic Bcg Vaccines Market Outlook 2025-2034: Market Share, and Growth Analysis

  • Report
  • 160 Pages
  • Global
From
Therapeutic BCG Vaccine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Therapeutic BCG Vaccine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 180 Pages
  • Global
From
Bacillus Calmette-Guérin (BCG) Vaccines - Global Strategic Business Report - Product Image

Bacillus Calmette-Guérin (BCG) Vaccines - Global Strategic Business Report

  • Report
  • 372 Pages
  • Global
From
Global BCG Vaccine - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030) - Product Image

Global BCG Vaccine - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)

  • Report
  • 115 Pages
  • Global
From

About the BCG Vaccine Market

The BCG Vaccine is a vaccine used to protect against tuberculosis (TB). It is the only vaccine available for TB prevention and is used in many countries around the world. The BCG Vaccine market is a subset of the larger Vaccines market, which includes a wide range of vaccines used to prevent and treat various diseases. The BCG Vaccine market is largely driven by the prevalence of TB in different countries, as well as the availability of the vaccine. The BCG Vaccine market is highly competitive, with many companies offering the vaccine. Some of the major players in the market include Sanofi Pasteur, GlaxoSmithKline, Merck & Co., Pfizer, and Serum Institute of India. Other companies in the market include Emergent BioSolutions, Bavarian Nordic, and Valneva. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.